Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 5Uterine Cervical Neoplasms 4Gliosarcoma 4Glioma 4Glioblastoma 4Ganglioneuroblastoma 4Pancreatic Neoplasms 3Neuroblastoma 3Vaginal Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Lung Neoplasms 2Glioma, Subependymal 2Ependymoma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Diseases 1

Interventions

Radiotherapy 119Temozolomide 109Carboplatin 52Filgrastim 46Vincristine 42Etoposide 39Cyclophosphamide 36Chemotherapy, Adjuvant 36Cisplatin 35Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 23Lomustine 22Thiotepa 21Methotrexate 19Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Topotecan 12Paclitaxel 12Ifosfamide 12Drug Therapy 12Thalidomide 11Radiation 11sargramostim 10Erlotinib Hydrochloride 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Neoplasms × Congresses as Topic × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡